A cognition drug platform changes hands for $12 million down

AlzeCure Pharma said on 12 August 2026 that it has received the full USD 12 million upfront payment from QuantumCell ApS and completed the initial transaction of their licensing agreement. The payment breaks down as a USD 7 million licence fee and a USD 5 million direct equity investment in AlzeCure. The agreement itself was signed on 1 July 2026; this is the money arriving and the first tranche closing.

What changes hands is the NeuroRestore platform and its lead candidate ACD856, a small-molecule positive allosteric modulator of Trk receptor signalling. Rather than supplying a missing neurotransmitter, a Trk-PAM raises the gain on signalling the brain is already doing through the NGF/TrkA and BDNF/TrkB pathways, which govern neuronal survival and synaptic plasticity. That places it among the few approaches aimed at cognitive function itself rather than at amyloid or tau.

Excluding royalties, the agreement is worth more than USD 2.2 billion in development and commercial milestones, with tiered royalties on future sales running from high single digits to low double digits. QuantumCell, based in Denmark, now carries the programme forward.

The compound has been through Phase 1 work; no Phase 2 efficacy result exists yet, and the milestone total describes what the deal could pay, not what has been earned.